Recombinant monoclonal antibody to Respiratory syncytial virus TNF. Adalimumab (HUMIRA, AbbVie) is the third TNF inhibitor, after infliximab and etanercept. Like infliximab and etanercept, adalimumab binds to Tumor necrosis factor-alpha (TNF?), preventing it from activating TNF receptors. Adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. TNF? inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases.